Supreme Court to hear PIL against Ranbaxy next week

Updated - November 17, 2021 05:35 am IST

Published - June 07, 2013 06:47 pm IST - New Delhi

A file picture of Ranbaxy CEO Malvinder Mohan Singh.

A file picture of Ranbaxy CEO Malvinder Mohan Singh.

The Supreme Court on Friday agreed to hear next week a PIL seeking cancellation of licence granted to Ranbaxy Laboratories, and for initiating probe against it for allegedly manufacturing and selling adulterated medicines.

“I have directed that the matter be listed (for hearing) next week,” a bench headed by Justice Gyan Sudha Misra said when lawyer M. L. Sharma mentioned the case this morning seeking early hearing of the PIL against the pharma major.

The PIL, filed in the wake of the company being fined $500 million by the US Food and Drug Administration (USFDA) for making and selling ‘adulterated’ drugs, has also sought sealing of all its manufacturing units here, including those in Paonta Sahib in Himachal Pradesh and Dewas in Madhya Pradesh.

Earlier, the bench, also comprising Justice Madan B Lokur, had asked petitioner’s lawyer to complete technical requirements in the registry before the matter can be considered for hearing.

The PIL has also sought a direction to prosecute the current and former directors the pharma company.

In his petition, the advocate has contended that making and selling adulterated drugs is a heinous crime and “amounts to committing murder” and a person who knowingly does it is liable to be prosecuted under the Indian Penal Code.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.